Literature DB >> 29186278

Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.

K Kahle-Wrobleski1, J S Andrews, M Belger, W Ye, S Gauthier, D M Rentz, D Galasko.   

Abstract

BACKGROUND: While functional loss forms part of the current diagnostic criteria used to identify dementia due to Alzheimer's disease, the gradual and progressive nature of the disease makes it difficult to recognize clinically relevant signposts that could be helpful in making treatment and management decisions. Having previously observed a significant relationship between stages of functional dependence (the level of assistance patients require consequent to Alzheimer's disease deficits, derived from the Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale) and cognitive severity, we investigated whether measures of functional dependence could be utilized to identify clinical milestones of Alzheimer's disease progression.
OBJECTIVES: To describe the patterns of change in dependence over the course of 18 months in groups stratified according to cognitive Alzheimer's disease dementia severity (determined using the Mini-Mental State Examination score) and to identify characteristics associated with patients showing worsening dependence (progressors) versus those showing no change or improvement (non-progressors).
DESIGN: Analysis of longitudinal data from the GERAS study.
SETTING: GERAS is an 18-month prospective, multicenter, naturalistic, observational cohort study reflecting the routine care of patients with Alzheimer's disease in France, Germany, and the United Kingdom. PARTICIPANTS: 1495 community-living patients, aged ≥55 years, diagnosed with probable Alzheimer's disease dementia, and their caregivers. MEASUREMENTS: Dependence levels, cognitive function, behavioral symptoms, caregiver burden, and cost were assessed at baseline and at 18 months.
RESULTS: Of 971 patients having both baseline and 18-month data, 42% (408) were progressors and 563 (58%) were non-progressors. This general pattern held for all three levels of baseline Alzheimer's disease dementia severity - mild (Mini-Mental State Examination score 21-26), moderate (15-20) or moderately severe/severe (<15) - with 40-45% of each group identified as progressors and 55-60% as non-progressors. No baseline differences were seen between progressors and non-progressors in cognitive scores or behavioral symptoms, although progressors had significantly shorter times since diagnosis and showed milder functional impairment. Baseline factors predictive of increasing dependence over 18 months included more severe cognitive impairment, living with others, and having multiple caregivers. A higher level of initial dependence was associated with less risk of dependence progression. Total societal costs of care also increased with greater dependence.
CONCLUSIONS: In this large cohort, 42% of Alzheimer's disease dementia patients at all levels of cognitive severity became more dependent within 18 months of observation while 58% did not progress. Dependence levels may be considered as meaningful interim clinical milestones that reflect Alzheimer's disease-related functional deficits, although a time frame that extends beyond 18 months may be necessary to observe changes if used in clinical trials or other longitudinal studies. Recognition of predictors of greater dependence offers opportunities for intervention.

Entities:  

Keywords:  ADCS-ADL; Alzheimer disease; GERAS; dependence; observational study

Mesh:

Year:  2017        PMID: 29186278      PMCID: PMC5912689          DOI: 10.14283/jpad.2017.2

Source DB:  PubMed          Journal:  J Prev Alzheimers Dis        ISSN: 2274-5807


  26 in total

1.  An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  D Galasko; D Bennett; M Sano; C Ernesto; R Thomas; M Grundman; S Ferris
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

2.  Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia.

Authors:  Hong Liu-Seifert; Eric Siemers; Karen Sundell; Karen Price; Baoguang Han; Katherine Selzler; Paul Aisen; Jeffrey Cummings; Joel Raskin; Richard Mohs
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

Authors:  Rachelle S Doody; Ronald G Thomas; Martin Farlow; Takeshi Iwatsubo; Bruno Vellas; Steven Joffe; Karl Kieburtz; Rema Raman; Xiaoying Sun; Paul S Aisen; Eric Siemers; Hong Liu-Seifert; Richard Mohs
Journal:  N Engl J Med       Date:  2014-01-23       Impact factor: 91.245

4.  Relatives of the impaired elderly: correlates of feelings of burden.

Authors:  S H Zarit; K E Reever; J Bach-Peterson
Journal:  Gerontologist       Date:  1980-12

Review 5.  The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.

Authors:  J L Cummings
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

6.  The effects of patient function and dependence on costs of care in Alzheimer's disease.

Authors:  Carolyn W Zhu; Christopher Leibman; Trent McLaughlin; Nikolaos Scarmeas; Marilyn Albert; Jason Brandt; Deborah Blacker; Mary Sano; Yaakov Stern
Journal:  J Am Geriatr Soc       Date:  2008-07-24       Impact factor: 5.562

7.  Reliability, validity, and interpretation of the dependence scale in mild to moderately severe Alzheimer's disease.

Authors:  William R Lenderking; Kathleen W Wyrwich; Marilyn Stolar; Kellee A Howard; Chris Leibman; Jacqui Buchanan; Loretto Lacey; Zoe Kopp; Yaakov Stern
Journal:  Am J Alzheimers Dis Other Demen       Date:  2013-12       Impact factor: 2.035

8.  The relation of patient dependence to home health aide use in Alzheimer's disease.

Authors:  Rachel K Scherer; Nikolaos Scarmeas; Jason Brandt; Deborah Blacker; Marilyn S Albert; Yaakov Stern
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2008-09       Impact factor: 6.053

Review 9.  Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.

Authors:  S Gauthier; A Leuzy; E Racine; P Rosa-Neto
Journal:  Prog Neurobiol       Date:  2013-04-08       Impact factor: 11.685

10.  Dependence in Alzheimer's disease and service use costs, quality of life, and caregiver burden: the DADE study.

Authors:  Roy W Jones; Renee Romeo; Richard Trigg; Martin Knapp; Azusa Sato; Derek King; Timothy Niecko; Loretto Lacey
Journal:  Alzheimers Dement       Date:  2014-07-26       Impact factor: 21.566

View more
  5 in total

Review 1.  The Humanistic and Economic Burden of Alzheimer's Disease.

Authors:  Amir Abbas Tahami Monfared; Michael J Byrnes; Leigh Ann White; Quanwu Zhang
Journal:  Neurol Ther       Date:  2022-02-22

2.  An investigation of microRNA-103 and microRNA-107 as potential blood-based biomarkers for disease risk and progression of Alzheimer's disease.

Authors:  Jie Wang; Chunyan Chen; Yun Zhang
Journal:  J Clin Lab Anal       Date:  2019-08-16       Impact factor: 2.352

3.  MiR-485-3p serves as a biomarker and therapeutic target of Alzheimer's disease via regulating neuronal cell viability and neuroinflammation by targeting AKT3.

Authors:  Ling Yu; Haiting Li; Wenhu Liu; Ligong Zhang; Qun Tian; Hairong Li; Min Li
Journal:  Mol Genet Genomic Med       Date:  2020-11-21       Impact factor: 2.183

4.  MicroRNA-4722-5p and microRNA-615-3p serve as potential biomarkers for Alzheimer's disease.

Authors:  Yan Liu; Yuhao Xu; Ming Yu
Journal:  Exp Ther Med       Date:  2022-01-26       Impact factor: 2.447

Review 5.  Utility of the Dependence Scale in dementia: validity, meaningfulness, and health economic considerations.

Authors:  Carolyn W Zhu; Bote Gosse Bruinsma; Yaakov Stern
Journal:  Alzheimers Res Ther       Date:  2018-08-13       Impact factor: 6.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.